Can You Test for Mold in Blood & What It Means

Several blood tests related to mold exist, but they measure very different things, and the one you’ve probably seen advertised online is the least scientifically supported. Clinically validated blood tests can detect mold-specific allergic antibodies or biomarkers of an active invasive fungal infection. What they cannot reliably do is tell you whether past exposure to mold in your home is responsible for a constellation of chronic symptoms. The gap between what these tests can and cannot reveal is where most of the confusion lives.

What Mold Allergy Blood Tests Measure

The most straightforward mold-related blood test is a specific IgE antibody test. Your immune system produces IgE antibodies when it treats a substance as an allergen, so measuring IgE levels against specific mold species can confirm a mold allergy. This is the same type of blood test used to diagnose allergies to pollen, pet dander, or dust mites. A doctor orders it when your symptoms, like sneezing, nasal congestion, or asthma flare-ups, suggest an allergic response and there’s reason to suspect mold as the trigger.

In one study of people exposed to mold indoors, about 11% of symptomatic individuals had elevated IgE antibodies against mold-derived antigens, confirming an IgE-mediated allergic response in that subset of patients.¹ That number may seem low, but it reflects the reality that not everyone who breathes in mold spores develops an allergy. Symptoms after mold exposure can have non-allergic causes too, including irritant effects on the airways.

A separate question is whether IgG antibodies to mold are useful. IgG antibodies get produced after exposure to all kinds of substances and tend to stick around for a long time. A study comparing exposed and non-exposed individuals found that specific IgE to a mold mixture was significantly more common in the exposed group (41% versus 17%), but IgG to a mold mixture showed no such difference.² In other words, IgE was a useful diagnostic marker for mold-associated respiratory symptoms, while IgG was not. If a practitioner orders a mold IgG panel and tells you elevated results prove ongoing mold illness, that interpretation goes beyond what the evidence supports.

When Blood Tests Diagnose a Serious Fungal Infection

For people with weakened immune systems, mold isn’t just an allergen. It can invade tissue and bloodstream, causing life-threatening infections called invasive mold infections or invasive fungal diseases. These overwhelmingly affect people undergoing chemotherapy, organ transplant recipients on immunosuppressive drugs, and others with severely compromised immunity. For this population, blood tests are a critical part of diagnosis.

Two well-established biomarkers are galactomannan (GM) and beta-D-glucan (BG). Galactomannan is a sugar molecule released by Aspergillus species as they grow, so detecting it in blood suggests an active Aspergillus infection. Beta-D-glucan is a component of the cell walls of many fungi, making it a broader marker. In one study, the BG test showed a sensitivity of about 78% and specificity of 85%, while the GM test had a lower sensitivity of 45% but a higher specificity of 93%.³ In practical terms, a positive GM result is quite reliable, while BG casts a wider net but with more false alarms.

The performance of these tests also depends on which fungal species is causing the infection. Research in patients with blood cancers found that the GM test was substantially better at detecting non-fumigatus Aspergillus species than the most common species, Aspergillus fumigatus (about 49% sensitivity versus 13%). BG, on the other hand, performed more consistently regardless of the infecting organism, with sensitivity in the range of 47% to 64% across different pathogens.⁴ This is one reason doctors often use both tests together rather than relying on a single marker.

Children present an additional challenge. Available evidence suggests that BG has limited accuracy in the pediatric population and isn’t recommended for diagnosing invasive mold infections in kids. Galactomannan from blood samples or lung fluid performs comparably to adult results and can be used as a screening tool in high-risk children who aren’t already on preventive antifungal medication.⁵

False Positives and the Limits of Fungal Biomarkers

One underappreciated problem with these biomarker tests is how often they give false-positive results. A study examining 49 separate batches of beta-lactam antibiotics (a very common class that includes penicillin-type drugs) found that roughly a third of batches triggered false positives on both the GM and BG assays.⁶ For patients who already have a bacterial bloodstream infection, the BG test had a false-positive rate of 37%, compared to just 2% for GM. So if you’re a hospitalized patient on antibiotics with a bacterial infection, a positive BG result may not mean you also have a fungal infection at all.

These false positives matter because the patients most likely to be tested are exactly the ones most likely to be on antibiotics and at risk for bacterial infections. The result is that no single blood biomarker should be used alone to make a diagnosis. Clinicians typically combine biomarker results with imaging, cultures, and clinical context before concluding that an invasive mold infection is present.

Newer PCR-Based Blood Tests

A more recent approach uses polymerase chain reaction (PCR) technology to detect fungal DNA circulating freely in blood plasma. Think of it as scanning the bloodstream for genetic fingerprints of specific fungi. Early results look promising, especially for Aspergillus. One study found that plasma cell-free DNA PCR for Aspergillus had a sensitivity of 86% and specificity of 93%, outperforming the traditional galactomannan test.⁷

A broader PCR panel covering multiple fungal species showed more varied performance. Overall sensitivity was about 57%, but this jumped to roughly 70% when an adequate blood sample volume was used. The test was especially good at catching Mucorales (the agents behind mucormycosis, sometimes called “black fungus”), with sensitivity above 90%, and also performed well for Candida, but had a harder time with Aspergillus species at around 56% sensitivity.⁸ The specificity was remarkably high at over 99%, meaning a positive result almost certainly represents a true infection. These PCR tests are still relatively new in clinical practice and not universally available, but they represent a genuine advance over older biomarkers for certain fungal infections.

Mycotoxin Blood and Urine Tests Are a Different Story

This is where things get contentious and where most people searching “can you test for mold in blood” are actually looking for answers. A cottage industry of labs and practitioners offers blood or urine panels that claim to detect mycotoxins, the toxic chemicals some molds produce. These tests are typically marketed to people who believe their chronic symptoms stem from living or working in a moldy building. The idea sounds reasonable on its surface: if mold produces toxins, why not test for them?

The problem is that these tests lack an established scientific foundation. Mycotoxins are small molecules that, on their own, cannot trigger the kind of immune response that produces specific IgG antibodies. They function as haptens, meaning they’re too small to be recognized by the immune system unless they’re chemically bonded to a larger protein carrier. Detecting IgG antibodies directed at isolated mycotoxins doesn’t have a validated immunological basis.⁹ On top of that, IgG antibodies reflect immunological memory of past encounters, not current exposure. So even if the test could work in theory, a positive result wouldn’t tell you about present-day exposure.

The urinary mycotoxin tests have their own issues. Everyone is exposed to some level of mycotoxins through food, since an estimated 60% to 80% of the world’s food crops carry detectable mycotoxin contamination.¹⁰ Detecting a mycotoxin in urine doesn’t distinguish between someone who ate grain-based foods and someone who inhaled toxins from a water-damaged wall. Without that distinction, the clinical usefulness of the result collapses. German medical guidelines are explicit on this point: blood or urine tests for particular mold components or metabolites are generally not indicated as part of a medical evaluation for mold exposure.¹¹

The CIRS Controversy

Many practitioners who order mycotoxin panels frame the results within a diagnosis called chronic inflammatory response syndrome, or CIRS. The concept holds that genetically susceptible individuals develop a persistent, multi-system inflammatory response after exposure to water-damaged buildings and the biotoxins they contain. Symptoms attributed to CIRS are wide-ranging: fatigue, brain fog, joint pain, headaches, shortness of breath, and many more. A newer line of research has proposed using transcriptomic profiling to identify disease stages and distinguish CIRS from other conditions that cause chronic fatigue.¹²

The tension here is real. People experiencing these symptoms are genuinely suffering, and some do improve when they leave moldy environments. But CIRS remains contentious in mainstream medicine because of its complex, overlapping symptomatology, lack of standardized diagnostic criteria, and limited recognition by major medical organizations.¹³ The biomarker panels associated with CIRS protocols, including markers like TGF-beta 1, MSH, VIP, and C4a, are legitimate lab tests individually but are not validated as a diagnostic panel for a single disease entity by any major medical society. A patient can easily spend hundreds or thousands of dollars on these panels and still not have a diagnosis that most physicians would accept.

This doesn’t mean mold exposure is harmless. It means the evidence supporting these specific testing protocols as diagnostic tools hasn’t reached the threshold that most of mainstream medicine requires. If you’re told you need a comprehensive panel of “mold toxicity” blood tests, it’s worth asking whether those tests are validated for the purpose they’re being used for and whether a conventional allergist or pulmonologist has evaluated you first.

Blood Tests in Diagnosing Allergic Bronchopulmonary Aspergillosis

One area where mold-related blood testing is well established and clinically powerful is in diagnosing allergic bronchopulmonary aspergillosis, or ABPA. This is a condition where the immune system overreacts to Aspergillus fungus growing in the airways, causing recurrent asthma-like symptoms, mucus plugging, and progressive lung damage if untreated. It’s most common in people who already have asthma or cystic fibrosis.

Diagnosis requires a combination of clinical features, imaging, and blood tests. The blood work typically includes total IgE levels (which are usually markedly elevated), specific IgE against Aspergillus, and sometimes specific IgG or precipitins.¹⁴ Newer approaches use IgE against specific recombinant Aspergillus proteins. Testing IgE against one particular protein yielded 89% sensitivity and 100% specificity for diagnosing ABPA, and combining two such protein targets brought sensitivity to 100% with specificity of 81%.¹⁵ For IgG, early research into a specific Aspergillus protein called Asp f 10 showed that IgG had excellent diagnostic capacity, with an area under the curve of 0.90 for distinguishing ABPA from other respiratory conditions.¹⁶

ABPA is worth knowing about because it’s one of the few conditions where mold truly causes serious, progressive disease in people who aren’t severely immunocompromised. If you have asthma that doesn’t respond well to standard treatment, especially with recurrent flares and thick mucus, asking your doctor about ABPA is reasonable. The blood tests for it are well validated and widely available.

What a Proper Clinical Workup Looks Like

Evidence-based guidelines for evaluating someone with suspected mold-related illness follow a structured approach. It starts with a thorough medical history and physical exam, focusing on whether you have risk factors like a compromised immune system or a history of atopic disease (conditions like asthma, eczema, or hay fever that signal an overactive allergic immune response).¹¹

From there, the workup branches depending on what the doctor suspects:

Allergic disease: Skin prick testing or specific IgE blood tests for mold species, sometimes supplemented by provocation testing when results are ambiguous.
Invasive infection: Imaging of the lungs or sinuses, cultures from tissue or fluid, and serum biomarkers like galactomannan, beta-D-glucan, or PCR. This pathway applies almost exclusively to immunocompromised patients.
ABPA: Total IgE, Aspergillus-specific IgE and IgG, lung imaging, and sometimes bronchoscopy.

What’s conspicuously absent from mainstream guidelines is routine testing of blood or urine for mycotoxins, indoor air sampling as a medical diagnostic tool, or broad “mold toxicity” panels. These guidelines don’t deny that mold exposure causes health problems. They direct clinicians toward tests that have been validated against known outcomes. If your immune system is compromised, the priority is removing you from the mold source immediately and investigating for invasive disease. If your immune system is intact, the investigation focuses on allergy and airway disease.

Mold Exposure and Respiratory Health Beyond Blood Tests

It’s easy to get caught up in the question of which blood tests to order and miss a more basic point: the strongest evidence linking indoor mold to health problems doesn’t require any blood test at all. Systematic reviews and longitudinal studies consistently show that visible mold and mold odor in homes are associated with the development and worsening of asthma in children, with enough evidence to support a causal relationship. The same body of evidence links mold exposure to allergic rhinitis and occupational asthma in adults exposed in work buildings.¹⁷

These findings are based on epidemiological data, not on blood biomarkers. In many cases, the most meaningful “test” is assessing the environment itself: is there visible mold, a musty odor, water damage, or high humidity? If so, remediating the problem and reducing exposure is the intervention most likely to help, regardless of what any blood test shows. A positive mold IgE result adds diagnostic certainty, but a negative result in someone living in a visibly moldy home doesn’t mean the mold isn’t making them sick through non-allergic irritant pathways.

For evidence-based studies in adult populations beyond children, the data is thinner and the conclusions more tentative. But even with limited evidence in adults, no credible guideline suggests that fixing a moldy home is anything other than a good idea. The practical takeaway for most people isn’t a blood test. It’s a dehumidifier, a leak repair, and a conversation with their landlord or a remediation specialist.